PhD Izidor Sosič

PhD Izidor Sosič
no.: 30816 source: ARIS

researcher – active in research organisation
  • English
  • Reading: Fluent
  • Writing: Fluent
  • Speaking: Fluent
  • Croatian
  • Reading: Functional
  • Writing: Functional
  • Speaking: Functional
  • German
  • Reading: Basic
  • Writing: Basic
  • Speaking: Basic
Edit
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   

Code Science Field
B740  Biomedical sciences  Pharmacological sciences, pharmacognosy, pharmacy, toxicology 
Keywords
targeted protein degradation; PROTACs; chimeric degraders; drug design; inhibitor; immunoproteasome; proteasome; BCL-2 family proteins; TAK1 kinase; antitumor compounds
Bibliography Representative bibliographic units | Personal | COBISS+
source: COBISS
source: SICRIS
Evaluation (metodology)
Evaluation of bibliographic research performance indicators according to ARIS methodology
source: COBISS
source: ARIS
Points
934.57
A''
203.61
A'
491.5
A1/2
711.73
CI10
1,853
CImax
145
h10
24
A1
3.43
A3
0
Data for the last 5 years (citations for the last 10 years) on December 27, 2025; Data for score A3 calculation refer to period 2020-2024
Data for ARIS tenders ( 21.05.2024 – Target research programmes, archive )
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Database Linked records Citations Pure citations Average pure citations
WoS 97  2,134  1,774  18.29 
Scopus 96  2,285  1,913  19.93 
Mentoring junior researchers
source: ARIS
no. Name and surname Type Period Code
1 PhD Nika Strašek Benedik   Bologna doctoral studies  10/1/2020 - 9/30/2024  52378 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group
Full time employment (120%, RD:20%)  University of Ljubljana, Faculty of Pharmacy  Chair for Pharmaceutical Chemistry 
Research projects Legend
source: ARIS
no. Code Title Period Head
1. N1-0331  A double whammy for the NF-κB signalling pathway: development of TAK1 and IKKβ degraders against inflammation-driven diseases   1/1/2024 - 12/31/2027  PhD Izidor Sosič   1,142 
2. J1-50038  New Hsp90 Inhibitor-based Therapies for Ewing Sarcoma   1/1/2024 - 12/31/2026  PhD Tihomir Tomašić   1,254 
3. J1-50037  Development of CDK1-selective degraders for the treatment of T-cell malignancies   10/1/2023 - 9/30/2026  PhD Izidor Sosič   1,336 
4. J3-50116  Matters of the heart: elucidating the cardiotoxic mechanism of proteasome inhibitors   10/1/2023 - 9/30/2026  PhD Martina Gobec   2,490 
5. BI-US/24-26-098  Mechanistic characterization of protein degraders with anti-cancer activity   7/1/2024 - 6/30/2026  PhD Izidor Sosič   300 
6. J3-3079  Bactericidal nanoblades: a proof-of-concept approach for bimodal chemo-mechanical eradication of persistent biofilms   12/1/2021 - 11/30/2025  PhD Stane Pajk   2,933 
7. J1-4417  Development of novel small molecule Toll-like receptors 7 and 8 modulators for cancer immunotherapy   10/1/2022 - 9/30/2025  PhD Matej Sova   4,387 
8. J1-4402  Dynamical model of a type II DNA topoisomerase biological nanomachine and design of catalytic inhibitors   10/1/2022 - 9/30/2025  PhD Andrej Perdih   2,966 
9. J1-4400  Evaluation of transient protein states   10/1/2022 - 9/30/2025  PhD Simona Golič Grdadolnik   3,570 
10. N1-0169  Kovalentni pristop k boju proti bakterijski rezistenci (Slovene)   1/1/2021 - 12/31/2023  PhD Stanislav Gobec   1,373 
11. J3-2517  Development of innate immune receptor-targeting chimeras as custom-tailored vaccine adjuvants   9/1/2020 - 12/31/2023  PhD Žiga Jakopin   2,528 
12. J1-2485  The kiss of death for key apoptosis players: development of BCL-2 and BAX PROTACs   9/1/2020 - 8/31/2023  PhD Izidor Sosič   1,146 
13. J1-1717  Development of novel Hsp90 inhibitors with anticancer activity   7/1/2019 - 6/30/2023  PhD Tihomir Tomašić   2,116 
14. J3-1745  Elucidating the role of immunoproteasome in platelet-driven immune response   7/1/2019 - 6/30/2023  PhD Martina Gobec   1,291 
15. Z1-7181  Optimization of nitroxoline-based inhibitors of cathepsin B as potential drugs for the treatment of cancer   1/1/2016 - 12/31/2017  PhD Izidor Sosič   300 
16. L1-6745  Boj proti bakterijski rezistenci: optimizacija zaviralcev biosinteze bakterijske stene (Slovene)   7/1/2014 - 6/30/2017  PhD Stanislav Gobec   3,580 
17. J1-6743  Razvoj računalniških orodij za modeliranje farmacevtsko zanimivih molekul (Slovene)   7/1/2014 - 6/30/2017  PhD Dušanka Janežič   3,050 
18. J4-6811  Vloga inhibitorjev cisteinskih proteaz v citotoksičnem delovanju naravnih celic ubijalk na tumorske celice (Slovene)   7/1/2014 - 6/30/2017  PhD Janko Kos   2,843 
19. J4-5529  Nitroksolin in njegovi derivati kot nova protitumorska zdravila (Slovene)   8/1/2013 - 7/31/2016  PhD Janko Kos   6,681 
20. L1-4039  Predklinični razvoj novih protimikrobnih učinkovin (Slovene)   7/1/2011 - 6/30/2014  PhD Stanislav Gobec   4,604 
ARIS research and infrastructure programmes Legend
source: ARIS
no. Code Title Period Head
1. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2022 - 12/31/2027 PhD Stanislav Gobec   6,035 
2. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2015 - 12/31/2021 PhD Stanislav Gobec   6,728 
3. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2009 - 12/31/2014 PhD Danijel Kikelj   6,592 
International projects
no. Code Title Period Head
1. CELSA/23/038  Degradation of CDK1 and HDACs as a strategy to treat T-cell malignancies   10/1/2023 - 9/30/2025    
We were not given permission by the researcher to publish data.
Confirmation required
Views history
Favourite